Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report, by Therapeutic Area (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN), by Dosage Form, by Type of Immunoglobulin, End User, By Region, Forecasts, 2025-2034

Report Id: 1874 Pages: 180 Last Updated: 14 July 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Intravenous Immunoglobulin Market-

Intravenous Immunoglobulin Market- By Therapeutic Area

  • Primary Immunodeficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Guillain-Barré Syndrome (GBS)
  • Immune Thrombocytopenic Purpura (ITP)
  • Multifocal Motor Neuropathy (MMN)

Intravenous Ig

Intravenous Immunoglobulin Market- By Dosage Form

  • Liquid
  • Lyophilized

Intravenous Immunoglobulin Market- By Immunoglobulin

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

Intravenous Immunoglobulin Market- By End User

  • Hospitals
  • Clinics
  • Homecare
  • Other End Users

Intravenous Immunoglobulin Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Intravenous Immunoglobulin Market Snapshot

Chapter 4. Global Intravenous Immunoglobulin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Therapeutic Area Estimates & Trend Analysis
5.1. by Therapeutic Area & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:

5.2.1. Primary Immunodeficiency
5.2.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.2.3. Guillain-Barré Syndrome (GBS)
5.2.4. Immune Thrombocytopenic Purpura (ITP)
5.2.5. Multifocal Motor Neuropathy (MMN)

Chapter 6. Market Segmentation 2: by Dosage Form Estimates & Trend Analysis
6.1. by Dosage Form & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Dosage Form:

6.2.1. Liquid
6.2.2. Lyophilized

Chapter 7. Market Segmentation 3: by Immunoglobulin Estimates & Trend Analysis
7.1. by Immunoglobulin & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Immunoglobulin:

7.2.1. IgG
7.2.2. IgA
7.2.3. IgM
7.2.4. IgE
7.2.5. IgD

Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User:

8.2.1. Hospitals
8.2.2. Clinics
8.2.3. Homecare
8.2.4. Other End Users

Chapter 9. Intravenous Immunoglobulin Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America
9.1.1. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.1.2. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.1.3. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.1.4. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.1.5. North America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.2. Europe
9.2.1. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.2.2. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.2.3. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.2.4. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.2.5. Europe Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.3. Asia Pacific
9.3.1. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.3.2. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.3.3. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.3.4. Asia-Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3.5. Asia Pacific Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.4. Latin America
9.4.1. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.4.2. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.4.3. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.4.4. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4.5. Latin America Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

9.5. Middle East & Africa
9.5.1. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
9.5.2. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Dosage Form, 2021-2034
9.5.3. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by Type of Immunoglobulin, 2021-2034
9.5.4. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5.5. Middle East & Africa Intravenous Immunoglobulin Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles

10.2.1. Bio Products Laboratory
10.2.2. Biotest
10.2.3. China biologics Products Holdings
10.2.4. CSL Behring
10.2.5. Grifols
10.2.6. Kedrion
10.2.7. LFB
10.2.8. Octapharma
10.2.9. Shanghai RAAS Blood products
10.2.10. Shire
10.2.11. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
2663
Security Code field cannot be blank!

Frequently Asked Questions

Intravenous Immunoglobulin Market Size is valued at USD 13.26 billion in 2024 and is predicted to reach USD 25.46 billion by the year 2034

Intravenous Immunoglobulin Market expected to grow at a 7.0% CAGR during the forecast period for 2025-2034

Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma,

Intravenous Immunoglobulin market is segmented into therapeutic area, dosage form, type of immunoglobulin, end user.

North America region is leading the Intravenous Immunoglobulin Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying